Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

New Leaf Biopharma Opportunities II, L.P.

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/23/2023

3. Issuer Name and Ticker or Trading Symbol

Harpoon Therapeutics, Inc. [HARP]

(Last) (First) (Middle)

C/O NEW LEAF VENTURES, 156 FIFTH AVENUE, SUITE 830

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

NEW YORK, NY 10010

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
8.000% Series A Redeemable Preferred Stock	10000 ⁽¹⁾	D ⁽²⁾⁽³⁾
Common Stock	913860	D ⁽²⁾⁽³⁾
Common Stock	2242839	I	See footnotes ⁽⁴⁾⁽⁵⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Warrant (Right to Buy) ⁽¹⁾	3/23/2023	3/23/2031	Common Stock	2994305	$0.9789	D ⁽²⁾⁽³⁾

Explanation of Responses:
(1)	Shares of the Issuer's non-convertible, non-voting 8.000% Series A Redeemable Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), were purchased by New Leaf Biopharma Opportunities II, L.P. ("BPO-II") in the Issuer's private placement of Series A Preferred Stock and warrants and pursuant to a Securities Purchase Agreement, dated March 22, 2023, by and among the Issuer, BPO-II and the other purchasers named therein. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation filed as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 27, 2023. The shares of Series A Preferred Stock and Warrants acquired by BPO-II were purchased at a price representative of $1,000 per share for the Series A Preferred Stock.
(2)	These shares are held directly by BPO-II. The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. ("NLBA-II"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. ("BPO Management-II"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
(3)	Each of Ronald M. Hunt, a Board member of the Issuer, and Vijay K. Lathi, are the managing directors of BPO Management-II (the "BPO-II Managers"), and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Hunt is a director of the Issuer and, accordingly, files separate Section 16 reports.
(4)	These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein.
(5)	Each of Mr. Hunt, a Board member of the Issuer, and Mr. Lathi, are the managing directors of Management-III (the "NLV-III Managers"), and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Mr. Hunt is a director of the Issuer and, accordingly, files separate Section 16 reports.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
New Leaf Biopharma Opportunities II, L.P. C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
New Leaf Ventures III, L.P. C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
New Leaf Venture Associates III, L.P. C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
New Leaf Venture Management III, L.L.C. C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
New Leaf BPO Associates II, L.P. C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
New Leaf BPO Management II, L.L.C C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X
Lathi Vijay K C/O NEW LEAF VENTURES 156 FIFTH AVENUE, SUITE 830 NEW YORK, NY 10010		X

Signatures
New Leaf Ventures III, L.P., By: New Leaf Venture Associates III, L.P., its general partner, By: New Leaf Venture Management III, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
New Leaf Venture Associates III, L.P., By: New Leaf Venture Management III, L.L.C., its general partner, by /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
New Leaf Venture Management III, L.L.C., By: /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
New Leaf Biopharma Opportunities II, L.P., By: New Leaf BPO Associates II, L.P., its general partner, By: New Leaf BPO Management II, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
New Leaf BPO Associates II, L.P., By: New Leaf BPO Management II, L.L.C., its general partner, By: /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
New Leaf BPO Management II, L.L.C., By: /s/ Craig Slutzkin, Chief Financial Officer		3/27/2023
^**Signature of Reporting Person		Date
/s/ Vijay K. Lathi Vijay K. Lathi		3/27/2023
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.